創造で、想像を超える。
中外製薬 (Chugai Pharmaceutical) (chugai-pharm.co.jp) scores 35 out of 100 on Brand Analyzer, placing it in the Early Stage tier among Healthcare brands, in the 0th percentile of 6232 Healthcare brands.
中外製薬 (Chugai Pharmaceutical) is a Switzerland company in Japan. It was founded in 1925. It is headquartered in Tokyo. 革新的な医薬品の創出を通じて、病気に苦しむ患者さんに貢献する。.
| Brand Name | 中外製薬 (Chugai Pharmaceutical) |
|---|---|
| Domain | chugai-pharm.co.jp |
| Industry | Healthcare |
| Founded | 1925 |
| Headquarters | Tokyo |
| Parent Company / Owner | Roche |
| Main Competitors | Takeda Pharmaceutical (87/100), Daiichi Sankyo (79/100), Astellas Pharma (90/100), Eisai (80/100), Roche (83/100), Novartis (75/100), Ono Pharmaceutical (63/100) |
Moz Domain Authority 53/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #131,437 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "「中外製薬」の社名および関係者を騙る勧誘・不審なメール、SNS投稿や広告等にご注意ください" (Meta description too short (1 words). OG description present but brief) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on Instagram; no detected presence on X (Twitter), LinkedIn, Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is 中外製薬 (Chugai Pharmaceutical)?", Claude could identify the brand as of September 2026. Chugai Pharmaceutical is a major Japanese pharmaceutical company headquartered in Tokyo, majority-owned by Roche, known for its research-driven focus on biotechnology and antibody drugs. It has developed notable therapies such as tocilizumab (Actemra), a treatment for rheumatoid Best known for Developing Actemra (tocilizumab) and other antibody-based biopharmaceuticals, and its close R&D partnership with Roche.
When asked "Best brands similar to 中外製薬 (Chugai Pharmaceutical)?", Claude would recommend 中外製薬 (Chugai Pharmaceutical) as of September 2026. It's one of Japan's leading innovative pharma companies with globally significant drugs, so it would naturally come up alongside firms like Takeda, Astellas, or Roche.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
中外製薬 (Chugai Pharmaceutical)'s main competitors in Healthcare: Takeda Pharmaceutical (87/100), Daiichi Sankyo (79/100), Astellas Pharma (90/100), Eisai (80/100), Roche (83/100).
Sources: Brand Analyzer scan
中外製薬 (Chugai Pharmaceutical) has limited AI-search visibility, scoring 33/100 on Brand Analyzer's AI visibility composite (visibility 30, trust 29, recommendation 43). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
中外製薬 (Chugai Pharmaceutical) was founded in 1925. 中外製薬 (Chugai Pharmaceutical) operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
中外製薬 (Chugai Pharmaceutical) is headquartered in Tokyo. 中外製薬 (Chugai Pharmaceutical) operates in the Healthcare category.
Sources: Wikidata
中外製薬 (Chugai Pharmaceutical) scores 43/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
中外製薬 (Chugai Pharmaceutical) can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
中外製薬(Chugai Pharmaceutical)は1925年に設立され、東京に本社を置く日本の研究開発型製薬企業です。革新的な医薬品の創出を通じて病気に苦しむ患者に貢献することを使命としており、スイスに関連する企業グループの一員としても知られています。
中外製薬 (Chugai Pharmaceutical) scores 33/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
中外製薬 (Chugai Pharmaceutical) has a weak AI-visibility profile at 33/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (43/100) and its weakest is trust (29/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #131,437 (Tranco) and a Moz Domain Authority of 53/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify 中外製薬 (Chugai Pharmaceutical) from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to 中外製薬 (Chugai Pharmaceutical): Sorfert (37/100), CVS Group (38/100), Asociatia Sanatatii prin Masaj (35/100), Maine Bodyworks (35/100).
A step up - brands to learn from: Werskincare (56/100), Mercè Puig | Espai de Salut (56/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.